Clinical Trials on Uncoupling Protein 1 in Japan

Total 327 results

AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Takeda

Active, not recruiting

A Study of TAK-662 for Japanese Patients With Congenital Protein C Deficiency

Congenital Protein C Deficiency

Japan
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Sanofi

Completed

Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

Non-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Pharmacological Study of MT-3921 in Subjects With HTLV-1 Associated Myelopathy (HAM)

HTLV-1-Associated Myelopathy (HAM)

Japan
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Safety and Pharmacokinetics of Alpha-1 MP (Alpha1-proteinase Inhibitor (Human), Modified Process) in Participants With Alpha1-Antitrypsin Deficiency

Alpha1-Antitrypsin Deficiency

Japan
Grifols Therapeutics LLC
Grifols Japan K.K.

Completed

Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Alpha1-Antitrypsin Deficiency

Japan
Eli Lilly and Company

Completed

A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Astellas Pharma Inc

Completed

Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Safety of Insulin Detemir in Children With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Pharmacokinetics of Insulin Detemir in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Efficacy and the Safety of Insulin Detemir in Subjects With Insulin Requiring Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Sanofi

Completed

Efficacy and Safety of Insulin Glulisine in Type 1 Diabetes Mellitus

Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Comparing Insulin Aspart With Fast-acting Insulin Human in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Effect of NN5401 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Patients With Type 1 or Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Type 1 or Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Paediatric Subjects - Special Survey

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey for Paediatric Subjects

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Novo Nordisk A/S

Completed

Special Survey of Production of Insulin Aspart Specific Antibody

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

Type 1 Diabetes Mellitus

Japan
Takeda

Completed

A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.

Hemophilia A

Japan
Ferring Pharmaceuticals

Completed

A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1 (HRS)

Hepatorenal Syndrome Type 1

Japan
Takeda

Completed

A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan

Multiple Myeloma

Japan
Takeda

Recruiting

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Acquired Hemophilia A

Japan
Takeda

Completed

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma"

Relapsed/Refractory Multiple Myeloma

Japan
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Takeda

Completed

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Relapsed and/or Refractory Multiple Myeloma

Japan
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Celgene

Completed

Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])

Multiple Myeloma

Japan
Chiba University

Completed

Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

POEMS Syndrome

Japan
GlaxoSmithKline

Active, not recruiting

An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma

Multiple Myeloma

Japan
AstraZeneca

Completed

Selumetinib Paediatric NF1 Japan Study

Neurofibromatosis Type 1

Japan
Pfizer

Completed

BeneFIX Drug Use Results Survey [All-Case Surveillance]

Hemophilia B

Japan
Novo Nordisk A/S

Enrolling by invitation

Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors

Haemophilia A | Haemophilia B

Japan
Astellas Pharma Inc

Completed

A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Eli Lilly and Company

Completed

Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

Multiple Myeloma

Japan
SymBio Pharmaceuticals

Terminated

Efficacy and Safety Study of SyB L-0501 for Patients With Multiple Myeloma

Multiple Myeloma

Japan
Novo Nordisk A/S

Completed

Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice

Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan

3

Subscribe